Teachers Retirement System of The State of Kentucky Has $1.04 Million Holdings in Charles River Laboratories International, Inc. (NYSE:CRL)

Teachers Retirement System of The State of Kentucky decreased its position in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 3.9% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 4,394 shares of the medical research company’s stock after selling 180 shares during the period. Teachers Retirement System of The State of Kentucky’s holdings in Charles River Laboratories International were worth $1,039,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently modified their holdings of the company. APG Asset Management US Inc. acquired a new stake in Charles River Laboratories International during the 4th quarter valued at $2,321,000. Norges Bank acquired a new stake in shares of Charles River Laboratories International in the fourth quarter valued at $101,319,000. abrdn plc raised its holdings in shares of Charles River Laboratories International by 872.0% in the fourth quarter. abrdn plc now owns 121,807 shares of the medical research company’s stock valued at $28,795,000 after buying an additional 109,275 shares during the last quarter. Regency Capital Management Inc. DE acquired a new position in Charles River Laboratories International during the 4th quarter worth about $3,703,000. Finally, Principal Financial Group Inc. grew its holdings in Charles River Laboratories International by 30.8% during the 4th quarter. Principal Financial Group Inc. now owns 152,537 shares of the medical research company’s stock worth $36,060,000 after acquiring an additional 35,921 shares during the last quarter. Institutional investors own 98.91% of the company’s stock.

Insider Activity at Charles River Laboratories International

In other Charles River Laboratories International news, EVP Joseph W. Laplume sold 1,304 shares of Charles River Laboratories International stock in a transaction dated Friday, May 10th. The stock was sold at an average price of $226.97, for a total transaction of $295,968.88. Following the transaction, the executive vice president now directly owns 23,276 shares in the company, valued at $5,282,953.72. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. 1.30% of the stock is owned by corporate insiders.

Charles River Laboratories International Price Performance

Charles River Laboratories International stock opened at $211.60 on Monday. The company has a current ratio of 1.75, a quick ratio of 1.37 and a debt-to-equity ratio of 0.73. The firm has a market capitalization of $10.90 billion, a P/E ratio of 24.89, a PEG ratio of 1.98 and a beta of 1.40. The business has a 50-day moving average of $222.48 and a 200-day moving average of $232.77. Charles River Laboratories International, Inc. has a 1 year low of $161.65 and a 1 year high of $275.00.

Charles River Laboratories International (NYSE:CRL) last issued its quarterly earnings data on Thursday, May 9th. The medical research company reported $2.27 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.05 by $0.22. The firm had revenue of $1.01 billion during the quarter, compared to analysts’ expectations of $997.24 million. Charles River Laboratories International had a net margin of 10.81% and a return on equity of 15.16%. On average, equities analysts anticipate that Charles River Laboratories International, Inc. will post 11 EPS for the current year.

Analyst Ratings Changes

CRL has been the subject of a number of research analyst reports. TheStreet raised shares of Charles River Laboratories International from a “c+” rating to a “b-” rating in a research note on Friday, March 1st. The Goldman Sachs Group initiated coverage on Charles River Laboratories International in a report on Thursday, June 6th. They set a “buy” rating and a $290.00 price objective on the stock. TD Cowen lowered their target price on Charles River Laboratories International from $260.00 to $228.00 and set a “hold” rating for the company in a research note on Monday, May 13th. Mizuho began coverage on Charles River Laboratories International in a research report on Friday, June 7th. They set a “neutral” rating and a $235.00 target price for the company. Finally, Robert W. Baird decreased their price target on Charles River Laboratories International from $282.00 to $270.00 and set an “outperform” rating on the stock in a report on Friday, May 10th. Six research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $256.38.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).